A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
暂无分享，去创建一个
Anton J. Enright | Anneliese O. Speak | A. Speak | G. Bignell | A. Enright | K. Dutton-Regester | S. van Dongen | D. Tamborero | N. Hayward | D. Adams | U. McDermott | F. Iorio | M. Garnett | Kim Wong | L. Wessels | M. Michaut | V. Iyer | A. Pritchard | O. Krijgsman | D. Peeper | J. Choudhary | N. Aben | Clara Alsinet | V. Grinkevich | Mamunur Rashid | J. Newton-Bishop | T. Roumeliotis | F. Behan | K. Yusa | Gemma Turner | K. Kemper | Chi C Wong | M. D. C. Velasco-Herrera | Marcela Sjoberg | M. Ranzani | J. Nsengimana | Nicola A. Thompson | Emmanuelle Supper | A. Shahrabi | Sofia Chen | Chi C. Wong | Stijn van Dongen